超声筛查与监测非酒精性脂肪性肝病谱系的新视野
非酒精性脂肪性肝病影响全球近四分之一成人,其进展型非酒精性脂肪性肝炎可进展为晚期纤维化/肝硬化甚至肝细胞癌。常规超声广泛用于筛查但存在固有缺陷,基于声学参数的定量超声技术可更准确评估脂肪变、坏死性炎症和纤维化/肝硬化。本文综述这些新兴超声技术的原理、可行性、准确性、可重复性和局限性,并讨论挑战与未来方向。
要点
- 定量超声技术可更准确评估NAFLD的组织学特征如脂肪变、炎症和纤维化。
- 常规超声筛查NAFLD存在固有弱点,推动声学参数定量技术发展。
- 综述涵盖各技术原理、可行性、准确性、可重复性及局限性。
局限性
- 摘要未报告综述的检索策略和纳入文献范围。
- 各定量超声技术的准确性和可重复性仍需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Non-alcoholic fatty liver disease (NAFLD) affects almost one quarter of adults worldwide, and its progressive subtype, non-alcoholic steatohepatitis can progress to advanced fibrosis/cirrhosis and even hepatocellular carcinoma. It is critical to screen and grade NAFLD patients for management decisions to rationalize the utilization of medical resources. Conventional ultrasound is widely applied for NAFLD screening, however, some inherent weaknesses hinder its utility. This limitation has spurred the development of acoustic parameters-based quantitative ultrasound techniques that allow a more accurate evaluation of the histological features of NAFLD (e.g. steatosis, necroinflammation, fibrosis/cirrhosis). Herein, this paper reviews the research advances in emerging ultrasound techniques for screening and surveillance across NAFLD spectrum and summarize their principles, feasibility, accuracy, reproducibility, and limitations of each technique. The challenges and future directions are also discussed to advance clinical practice.
引用
- Guan, Chen, Xu, et al. New horizon of ultrasound for screening and surveillance of non-alcoholic fatty liver disease spectrum. Eur J Radiol. 2022. PMID: 35917757. doi:10.1016/j.ejrad.2022.110450
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。